Foghorn Therapeutics Doses First Patient With FHD-909 In Phase 1 Trial For SMARCA4 (BRG1) Mutated Cancers, With Non-small Cell Lung Cancer As Primary Target Patient Population
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics has initiated a Phase 1 trial for its drug FHD-909, targeting SMARCA4 (BRG1) mutated cancers, with a focus on non-small cell lung cancer. This marks a significant step in their clinical development pipeline.
October 10, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Foghorn Therapeutics has dosed the first patient in a Phase 1 trial for FHD-909, targeting SMARCA4 mutated cancers, primarily non-small cell lung cancer. This development could enhance Foghorn's clinical pipeline and investor interest.
The initiation of a Phase 1 trial is a critical milestone for Foghorn Therapeutics, indicating progress in their drug development efforts. This could lead to increased investor confidence and potential stock price appreciation as the trial progresses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100